NCT07652645 Hybrid Dialectical Behavior Therapy for Veterans to Further Reduce Emotion Regulation Problems and Trauma Symptoms
| NCT ID | NCT07652645 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Arkin |
| Condition | PTSD |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2026-06-01 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Around 10% of post-active veterans experience post-traumatic stress disorder (PTSD) many years post-mission. PTSD in veterans is frequently associated with challenges in emotion regulation, aggression, suicidality, and financial and psychosocial stress. In 2018, a 12-week clinical treatment programme, the Veterans Intensive Treatment Unit (VIBU), was developed for veterans experiencing these psychiatric symptoms, for whom conventional treatments had proven ineffective. The VIBU provides patients with trauma-focused and dialectical behaviour therapy (DBT). A recent study revealed that the VIBU was effective in reducing psychiatric symptoms. However, a recurrence of symptoms was observed in patients a few months after discharge. Consequently, an aftercare programme consisting of hybrid DBT is offered to consolidate and repeat the DBT skills and apply them in daily life.
Eligibility Criteria
Inclusion Criteria: * Adult veteran (18 years or older), treated at Sinai Center, with knowledge of DBT * Primairy diagnosis of PTSD, determined with CAPS-5, resulting from war-related traumas * Stable for four weeks on their medication (type and doses) * Able to to do online homework assignments and communicate with their therapist via an eHealth platform * Dutch speaking Exclusion Criteria: * Chronic psychosis (psychotic features as comorbidity from PTSD is allowed) or bipolar disorder type 1 * IQ below 80 or cognitive disorders * Severe self-harming behaviour, such as auto-mutilation or suicidal ideations as main problem * Following day treatments or other intensive treatment for residual symptoms
Frequently Asked Questions
Who can join the NCT07652645 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying PTSD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07652645 currently recruiting?
Yes, NCT07652645 is actively recruiting participants. Visit ClinicalTrials.gov or contact Arkin to inquire about joining.
Where is the NCT07652645 trial being conducted?
This trial is being conducted at Amstelveen, Netherlands.
Who is sponsoring the NCT07652645 clinical trial?
NCT07652645 is sponsored by Arkin. The trial plans to enroll 24 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.